There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Achieve Life Sciences (ACHV – Research Report), ClearPoint Neuro (CLPT – Research Report) and OptimizeRx (OPRX – Research Report) with bullish sentiments.
Achieve Life Sciences (ACHV)
Lake Street analyst Thomas Flaten maintained a Buy rating on Achieve Life Sciences today and set a price target of $11.00. The company’s shares closed last Monday at $4.42.
According to TipRanks.com, Flaten has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Achieve Life Sciences with a $19.67 average price target, a 346.0% upside from current levels. In a report issued on February 29, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $30.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ClearPoint Neuro (CLPT)
In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on ClearPoint Neuro. The company’s shares closed last Monday at $6.50.
According to TipRanks.com, Takkinen is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ClearPoint Neuro with a $9.00 average price target, a 32.9% upside from current levels. In a report issued on February 22, B.Riley Financial also reiterated a Buy rating on the stock with a $10.00 price target.
OptimizeRx (OPRX)
Lake Street analyst Eric Martinuzzi maintained a Buy rating on OptimizeRx today and set a price target of $17.00. The company’s shares closed last Monday at $16.12, close to its 52-week high of $17.77.
According to TipRanks.com, Martinuzzi is a 4-star analyst with an average return of
Currently, the analyst consensus on OptimizeRx is a Moderate Buy with an average price target of $16.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACHV:
- Achieve Life Sciences Raises Funds for Clinical Trials
- Achieve Life reaches agreement with FDA on cytisinicline data requirements
- Achieve Life Sciences sells 13M shares at $4.585 in registered direct offering
- Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
